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Abstract
In this review, we discuss recent advances on the plasticity of cancer stem cells and highlight
their relevance to understand the metastatic process and to guide therapeutic interventions. Re-
cent results suggest that the strict hierarchical structure of cancer cell populations advocated by
the cancer stem cell model must be reconsidered since the depletion of cancer stem cells leads
the other tumor cells to switch back into the cancer stem cell phenotype. This plasticity has
important implications for metastasis since migrating cells do not need to be cancer stem cells
in order to seed a metastasis. We also discuss the important role of the immune system and the
microenvironment in modulating phenotypic switching and suggest possible avenues to exploit
our understanding of this process to develop an effective strategy for precision medicine.
Keywords: , cancer stem cells, phenotypic switching, metastasis, precision medicine
Do tumors grow stochastically or hierarchically?
Two main models have been used in the past to describe tumor development: in the stochas-
tic clonal evolution model [1], each cells can be tumorigenic and sustain tumor growth, while
according to the cancer stem cell (CSC) theory [2], the tumor is organized hierarchically with
a subpopulation of cells sustaining the growth. The relevance of either one or the other theory
has a relevance for therapeutic strategies [3, 4]. Whereas the stochastic model suggests that the
best therapeutic strategy is to kill all cancer cells targeting some common factors, according to
the CSC theory the best strategy should be to primarily target CSCs inside the heterogeneous
population. The main idea coming from this debate is that once we answer the question of how
tumors evolve, either stochastically or hierarchically, we could tackle the issue of the impact
of each theory on metastasis. There are papers providing strong evidence of the existence of a
CSCs population in different tumors, including observations in vivo [5], but contrasting results
appeared regularly in the literature. A possible explanation for this controversy might come from
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plasticity: the possibility that cancer cells might revert to the CSC state [6, 7, 8, 9, 10, 11]. In the
following we will discuss this issue, focusing on the relevance to metastasis.
The CSC was defined like a cell within the tumor that has the capacity of self-renewing and
generating an heterogeneous population of cancer cells composing the tumor [3, 4]. Contrary to
normal stem cells, however, where the proliferation capabilities and genomic integrity are tightly
regulated and controlled, in CSCs these controls are typically missing. In practice, CSCs can
only be defined experimentally by their ability to recapitulate the generation of a continuously
growing tumor. To this end, putative CSCs were identified according to the expression of surface
markers (e.g factors expressed by normal stem cells) and isolated through fluorescence-activated
cell sorting (FACS). The cells isolated in this way are then transplanted (or engrafted) in immuno-
compromized mice. If the mouse develops a tumor, cancer cells expressing the CSC markers are
again isolated and transplanted into mice (Fig 1) The observation of a series of CSC identifica-
tions and transplantations is considered an evidence for the existence of a CSC population within
the tumor. Both xeno- and syngeneic transplantations might, however, misrepresent the intricate
network of interactions with diverse support such as fibroblasts, endothelial cells, macrophages,
mesenchymal stem cells and many of the cytokines and receptors involved in these interactions
([12]). Another important problem is that there is no clear recipe to choose the best marker to un-
ambiguously identify CSCs. One is thus forced to proceed by trial and error, exploiting analogies
with normal stem cells.
Taken in account all these limitations, the first evidence of CSCs came from hematological tu-
mors [2] and later from solid tumors such as breast [13, 14, 15], prostate [16], brain cancer [17]
and melanoma [18, 19, 20, 21, 22, 23]. In breast cancer, the first evidence of a subpopulation
with a specific cell-surface antigen profile (CD44+/CD24-) that successfully establish itself as
tumor xenograft was published in 2003 [13]. In another study, 275 patients were analyzed for
CD44+/CD24- putative stem cell marker as well as for others (vimentin, ostenectin, connexin
43, ADLH, CK18, GATA3, MUC1) in primary breast cancers of different subtypes and hysto-
logical stages. This study reveals a high degree of diversity in the expression of several of the
selected markers in different tumor subtypes and hystologic stages [14]. Furthermore, aldehyde
dehydrogenase (ALDH) was used as stem cell marker in 33 human breast cell lines [15]. ALDH
is a detoxifying enzyme that oxidizes intracellular aldehydes and it is thought to play a role in
the differentiation of stem cells via the metabolism of retinal to retinoic acid [24]. Interestingly,
ALDH activity can be used to sort a subpopulation of cells that display stem cell properties from
normal breast tissue and breast cancer [25] and to isolate CSCs from multiple myeloma and
acute leukemia as well as from brain tumors [26, 27]. The ALDH phenotype was not associated
with more-aggressive subpopulations in melanoma, suggesting that it is not a ”universal” marker
[28]. Several markers that select aggressive subpopulations have been identified in glioblastoma
multiforme [17]. Similarly, several candidate populations of prostate stem/progenitor cells have
been reported including those expressing high levels of CD44, integrin α2β1, or CD133 [16].
Interestingly, two independent studies in the mouse prostate have identified two different stem
cell populations. One, marked by CD117 (c-Kit), seems to be localized in the basal layer [29]
and and the other, called castration-resistant Nkx3.1-expressing cells, in the luminal layer [30].
Identification and characterization of normal prostate stem cells is clearly relevant to understand
the origin for human prostatic cancer [31]. This is because it is difficult to ascertain the poten-
tial overlap as well as lineage relationships of the various candidate stem cells that have been
identified [32]. This in part is due to the distinct methodologies and assays employed [32].
Considering melanoma, several papers provided evidence supporting the existence of a CSCs
subpopulation [18, 19, 20, 21, 22, 23]. In 2008, however, a paper argued against CSCs based on
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the following observations: a relatively large fraction of melanoma cells (up to 25%) was shown
to initiate tumors in severely immunocompromised NOD/SCID IL2Rγnull mice; the fraction of
tumor-inducing cells depended upon assay conditions; several putative CSC markers appeared to
be reversibly expressed [33]. The paper suggested that the best experimental model to confirm
the presence of CSCs is severe immunocompromised mice. The authors analyzed the expres-
sion of more than 50 surface markers on melanoma cells derived from several patients (A2B5,
cKIT, CD44, CD49B, CD49D, CD49F, CD133, CD166) but then mostly focused on CD133 and
CD166 [33]. In a more recent paper it was shown that CD133 is highly expressed in melanoma
cells and it is not a good marker to sort CSCs [22]. Moreover in 2010, an independent group,
using the same immunocompromised mice as in Ref. [34], did not confirm those results and
proposed instead to use CD127, the nerve growth factor receptor, as a marker to identify CSCs
[35]. Finally, CXCR6 was proposed as a marker for a CSC-like aggressive subpopulation in hu-
man melanoma cells [36]. Its peculiar feature is that it plays a critical role in stem cell biology,
being linked to asymmetric cell division [36]. Recent experiments in vivo have confirmed the
presence of an aggressive CSC-like subpopulation in benign and malignant intestinal and skin
tumors [37, 38, 39]. Contrary to previous work based on sorting and serial transplantation, these
new papers tracked CSCs directly inside a growing tumor and studied the CSC population at
different stages of tumor progression [37, 38, 39]. Another in vitro approach that was used in
recent years to investigate CSCs is to study the capability of tumor cells to form tumorospheres.
The general idea is that cancer cells would not be able to form tumorspheres since they differ-
entiate, while CSCs, resembling the characteristic of normal stem cells, can growth in a sphere.
The impact of the presence of tumorspheres in physiological process like as angiogenesis and
mutidrug resistance has also been studied [17].
A marker of CSCs that is ubiquitous expressed is CD133, also known as promonin-1. This is
a membrane-bound pentaspan glycoprotein that is frequentely expressed on CSC and is linked
to self-renewal and tumorigenicity. CD133 is expressed in fact in hematopoietic stem cells [40]
and was found in neural stem cells [41]. It is now considered as a marker for progenitor cells.
However, in many tumors such as melanoma it is not only restricted to CSC subpopulation [21].
Therefore the advantage to use this marker is that is expressed by many CSC-tumor subpopula-
tion but on the other side it is not always specific for CSCs. CD133 is also related to metastasis
such as in gastric cancer patients and colorectal cancer [42, 43]
Despite the accumulated experimental evidence, the population dynamics of CSCs is still de-
bated: in 2011 a paper pointed out the possibility that non-CSCs breast cancer cells can revert
to a stem cell like state even in the absence of mutations [6]. Similarly in melanoma, a small
population of CSC-like JARID1B positive cells has been shown to be dynamically regulated in
a way that differs from the standard hierarchical CSC model [44]. This finding could reconcile
the conflicting results on the existence of CSCs in melanoma [33, 34, 35]. Microenvironmental
factors, such as TGFβ, are found to enhance the rate of switch from non-CSC cells to the CSC
state [45]. This is in agreement with earlier results from our group showing that ABCG2 nega-
tive cells isolated from human melanoma biopsies express again this marker after few passages
in vitro [21]. The idea that the environment is able to induce cells to switch into a more ag-
gressive phenotype was confirmed by Medema and Vermeulen who tried to limit stemness by
modifying microenvironmental factors known to support CSCs in tumors [46]. While mounting
experimental evidence supports the switch from non-CSC cancer cells to the CSC state, the bi-
ological factors regulating this process are still being investigated. Two possible scenarios have
been invoked to solve this puzzle: i) switch to the CSC state is either driven by genetic mutations
or ii) it is regulated by epigenetic factors [47].
3
Therefore the general view discussed above that only two possible scenarios are possible for
tumor development, the CSC theory or the stochastic one, appears too simple. A new concept
comes into the discussion: the cellular plasticity of CSC. Many groups, including ours, proposed
the concept that there is an equilibrium between CSCs and their more differentiated progeny
[6, 7, 8, 9, 10, 11]. In light of these evidence, not only the cancer cells can become CSCs but
the reverse process can also happen. Our group investigated the possible factors involved in this
phenotypic switching, demonstrating that human melanoma cells can switch their phenotype to
the CSC state thanks to the activation of a complex miRNA network [11]. In particular, our
group showed that phenotypic switching is not a stochastic process as originally assumed [6]
but it is tightly controlled by a complex network of miRNAs which in turn regulates critical
pathways, such as Wnt and PI3K, leading to phenotypic switching [11]. This miRNA network
is activated when the CSCs are below a specific threshold implying that cancer cells are sensitive
to the number of CSCs in the bulk, as also happens for normal stem cells. Accordingly, in
stem cells the locality of Wnt signaling dictates differentiation and spatial confinement in a niche
[48]. A direct consequence of our findings is that if a reduced number of CSCs induce the
other cancer cells to switch back to the CSC state. Hence, trying to kill specifically the CSCs
does not represent an effective therapeutic strategy. The capability of cancer cells to switch to
CSC under specific conditions reconcile all the contrasting reported literature. Another important
consequence of these findings is that CSCs live in a niche that means a distinct microenvironment
with specific functional characteristics that form the habitat of the cells. The possibility to target
the niche instead of the cells could be an important way to overcome cellular resistance and
prevent metastasis.
Phenotypic switching and cancer metastasis
Metastasis represents the main problem for cancer treatment. Melanoma is a good example:
most of the time whenever this tumor is diagnosed there is a high probability that a metastasis is
already present. When a metastatic melanoma is diagnosed there are few available therapeutic
strategies and their rate of success is low. The organs affected by metastasis depend on the proba-
bility that metastatic cancer cells reach distant organs, but also survive and grow there, initiating
further metastasis. Disseminated cancer cells need supportive sites to establish a metastasis, in
a way that is reminiscent of stem cell niches. For stem cells, the location and constitution of
stem cell niches has been demonstrated in various tissues, including the intestinal epithelium,
hematopoietic bone marrow, epidermis, and brain. In a similar way, the term metastatic niche
is used to designate the specific locations, stromal cell types, visible signals, and ECM proteins
that support the survival and self-renewal of disseminated metastatic cells. Metastatic cells could
occupy a stem cell niche including perivascular sites recruiting stromal cells that produce stem
cell niche-like components or by producing these factors themselves. Some tumors release sys-
temic suppressor factors that make micrometastasis dormant, but others, such as melanoma, erupt
decades after a primary tumor has been eradicated surgically or pharmacologically, possibly due
to a reactivation of dormant micrometastasis. Recent papers show that nutrient starvation can
induce autophagy causing the cancer to shrink and adopt a reversible dormancy. When the tissue
changes becoming more accessible to nutrients, the tumor restarts to grow [49]. Up to now, this
relationship between genetic factors and microenvironment is still debated: it seems plausible
that both factors contribute to metastasis.
The possibility that cancer cells can switch into CSCs under specific conditions dictated by
a depletion in the number of CSCs or by the environments, opens a new perspective on the
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metastatic process. The metastatic process is usually intrepreted based on the idea that each
metastasis arises from the clonal growth of a single tumor cell that has detached from tumor
mass and migrated elsewhere (see Fig. 2). According to the CSC model, a CSCs should undergo
an epithelial-mesenchymal transition and then migrate to a distant site where it would seed a
metastasis. The picture changes, however, if pheotypic plasticity is present: the migrating cell
in this case could be a cancer cell that would then switch into a CSC at the metastatic site.
For the sake of clarity, notice that in the discussion above we mention two distinct phenotypic
transformation: the epithelial-mesenchymal transition and the switching from a cancer cell to
the CSC state. Throughout this review the term ”phenotypic switching” is only reserved to the
second process. If phenoptypic switching is induced by the absence of CSCs in the population,
as demonstraded in [11], then a migrating cancer cell would automatically switch into a CSC
once it has spread far enough from the primary tumor (see Fig. 2). This observation is important
because CSCs typically represent a small fraction of the cancer cell population and therefore their
migration would be statistically unlikely. On the other hand if all cancer cells are potentially able
to seed a metastasis by switching, the process would occur with higher probability than expected
from the CSC model.
The capability to switch is driven by the microenvironment. For instance, the exposure of
non stem breast cancer cells to transforming growth factor beta (TGF-β) has been shown to
produce mesenchymal/CSC-like cells with a high degree of plasticity, whereas removal or in-
hibition of TGF-β causes the cells to lose their mesenchymal/CSC-like characteristics, and to
regain an epithelial and non-stem cell phenotype [50]. Acquiring a mesenchymal phenotype,
CSCs express characteristics that promote tumor progression recurrence, metastasis, and resis-
tance to therapy [51]. In a recent study, two metastatic breast cancer cell lines were exposed to
repeated hypoxia/reoxygenation cycles, reproducing the typical microenvironment observed in
solid tumors [52]. After one cycle of hypoxia and reoxygenation, a small subset of cells survive
the hypoxia, forming spherical clusters which proliferate after reoxygenation [52]. After three
of those cycles, the authors observed the appearance of a novel cell subpopulation, expressing
surface marker expression (i.e., CD44++/CD24-/ESA+) associated with breast CSCs and char-
acterized by high tumorigenicity [52]. Interestingly, this new subpopulation was reported to
display a high fraction of CSC-like cells with respect to the original breast cancer cell lines and
a stronger metastatic capacity [52].
The strict interplay between the plasticity of the cells and the microenvironment can thereby
affect the tumor evolution and in particular the metastasis.
Limitation of current therapies for metastasis
CSCs are resistant to chemotherapy and/or radiotherapy [53, 54, 55, 56]. The resistance might
be due to multiple factors: the tumor microenvironment which is typically rich in a diversity of
proteins, including growth factors (e.g., TGF-β) and cytokines, that could activate pathways that
impact the survival of CSCs [57] and the possible role of chemo/radiotherapy in the acquisition
of stemness. In fact, the problem of resistance of CSCs to conventional cancer therapies is not
simply a matter of an inability of chemotherapy and radiation to destroy the CSCs but rather that
the treatment itself has been shown to increase CSC characteristics in CSs, and can even convert
non stem cancer cells to CSCs [58, 59, 60] . Studies in breast cancer found that irradiation of
breast cancer cells resulted in an increase in the number of CSCs and, in some cases, converted
non tumorigenic cancer cells into CSCs [58]. Recently, it has been found that human gastric
cancer cell lines, after exposure to the chemotherapy agent 5-fluorouracil (5-FU), exhibited both
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resistance to 5-FU and features consistent with stemness, including tumorigenicity and capacity
for self-renewal [60]. Another important example is ALDH1 which confers resistance to alkylat-
ing chemotherapeutic agents and protect against oxidative damage [61, 62]. In colorectal cancer
was shown a relationship between ADLH1 expression between metastatic and non-metastaic col-
orectal tumors: the latter expressing high levels of ADLH1 [63]. In breast cancer a recent paper
showed an increase of putative CSCs and ADHL1 positive cells after primary systemic therapy
[64]. Furthermore, in head and neck cancer cells increased expression of ALDH1 led to increase
expression of CSCs markers while its inhibition to a descrease of these factors [65]. Another im-
portant factor, ABCG2, was shown to be related with chemoresistant. For example, in colorectal
cancer it has been shown that the down regulation of ABCG2 inhibited the self-renewal capacity
of these cells, enhancing the efficacy of chemotherapic-induced apoptosis [66]. High levels of
ABCG2 was found associated to CSC-like phenotype in human melanoma [21]. All these data
are in agreement with the data showing that the number of CSCs are under a strict control and
decreasing below a threshold increases their numbers [11]. This is the key factor that drives the
plasticity of the tumor cells. Taking in account this new information, a successful strategy might
be to impair phenotypic switching by manipulating either the cells or the microenvironment. To
achieve this result, however, it is important to better understand the mechanisms that lead to
phenotypic switching. On the other hand, if we think to kill the CSCs the effect is the reverse:
increase the numbers of CSCs and therefore more markers linked to a CSC-like phenotype as
described above. On the other hand, another aspect should be consider: the resistance induced
by the drugs ion the CSC’s niche. In a recent interesting paper, the authors showed a chromatin-
dependent mechanism exerted by let-7 which down-regulates stemness genes in cancer cells ,
this suggesting that epigenetic mechanisms happening in the niche are crucial for drug tolerance
[67]. Similarly, in leukemia cells an alteration in the niche has been demonstrated and there-
fore a remodelling of the niche can be a good strategy to fight the cancer [68]. The mechanical
connection with the niche of the cells has been shown also to be a crucial factor for conversion
of differentiated mouse cells into a tissue-specific stem/progenitor cell state through YAP-TAZ
[69]. In fact, YAP/TAZ has been shown to be able to reprogram distinct cell types to their corre-
sponding tissue specific stem cells [69]. YAP has been shown to be regulates by the expression
of cytoskeletal regulators and matrix stiffness can enhance YAP activation [70]. Altogether we
can speculate that changes in the mechanical and chemical structure of the niche can help in
reprogramming the cells and therefore in cancer stem plasticity. These aspects appear crucial to
develop anew therapeutic approach. On one side it is possible to think to investigate better the
factors that create the niche and how and if mechanical or chemical changes can alter it.
CSCs, metastasis and the immune system
It is widley accepted that the immune system is recognized and respond to tumor cells. Anti-
gens released by the tumor cells can be passively transported in the lymph or captured and de-
livered by dendritic cells (DC) to regional lymph nodes via afferent lymphatic vessels. In tumor-
draining lymph nodes, DCs present tumor-derived antigen in associtaion to MHC molecules and
activate lymphocytes CD4+T and CD8 T effector cells can exit the lymph node and circulate
throughout the body via the bloodstream following the gradient of chemokines and adhesion
molecules, extravasate and migrate into the tumor bed where they recognise the cells display-
ing the antigens and kill them. In principle therefore, the cancer-immunity cycle could lead to
eradication of malignant cells by cytotoxic immune cells, establish tumor-specific immunolog-
ical memory and prevents further tumor progression. The situation is however more complex:
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it could be a periferal tolerance; the migration of T cells into the tumor bed can be hindered
by the disorganized vasculature and chemotactic cues [71]. The presence of inhibitor cells and
molecules could impair the survival of T cells, their activation, proliferation and effector func-
tions. A general example could be the limited therapeutic benefit of the use of antibodies against
PDL1 which is often overexpressed in tumor cells, possibly due to the lack of pre-existing anti-
tumor immunity or to the presence of other immunosuppressive mechanisms in the microenvi-
ronment. The tumor can escape from the immune surveillance using different mechanisms: from
the production of immunosuppressive molecules that attenuate the immune system, to the loss of
antigen expression and/or co-stimulators, to the activation of immune suppressive factors. The
possibility to use an immunotherapy strategy in an advanced and metastatic tumor is quite far to
be realised. The best way forward appears to be the possibility to kill all the cells, both CSC and
cancer cells, but in this case the toxicity could be relevant. The use of vaccines could be more
interesting than the passive immunization through adoptive T cells. In fact, if the phenotypic
switching mechanisms will be fully understood, it might be possible to target with a vaccine all
the tumor cells in a way that do not allow them to switch. In a recent interesting paper, the au-
thors showed that using a gene-transduced tumor cell vaccine therapy targeting CSCs they found
a substantially suppression in syngenic immunocompetent mice recapitulating normal immune
systems [72]. This system seems very interesting to induce potent tumor-specific antitumor im-
munity [72]. Moreover, considering the plasticity of both the tumor cells and the plasticity of
immune system,the interaction between the two compartment might be protumorigenic or an-
titumorigenic. In another recent paper, the authors proposed another strategy to target CSCs
suing lysate-pulsed dendritic cells in melanoma and squamous cell carcinoma [73]. The CSC-
DC vaccine reduced significantly ALDH-high expressed CSCs in primary tumors and therefore
seems to be useful in the adjuvant setting where local and systemic relapse are high after con-
ventional treatment of cancers [73]. The CSC’s niche as well as the interplay with the immune
system might be an important filed to investigate. In this connection, an interesting theoretical
paper showed that an up-regulation of glucose by tumors which can lead to active competitive
resources in the tumor microenvironment between tumors and immune cells [74]. In particular,
they proposed that CSCs can circumvent by a protective shield of cancer cells creating a barrier
against the immune system and creating a competition for common resources such as glucose
between the same cells and immune cells [74]. Natural killers are also interesting in view of a
immune therapy. A recent paper showed that activated natural killers targeted more CSCs and
therefore they might be used in immunotherapy for refractory solid malignacies suchaas metas-
tasis [75].
Conclusion: Precision medicine and tumor plasticity
The idea to develop a therapeutic strategy considering the heterogeneity between the patients is
already mainstream in the field of tumor biology. Our new understanding of tumor plasticity and
the important role of the microenvironment controlling this process provides a concrete answer
to the quest for precision medicine. The discovery of phenotypic switching into CSCs leads to
challenges to existing therapeutic strategies but it also opens possible new avenues. If cancer
cells can switch back into CSCs, then targeting CSCs would be counterproductive since it would
ultimately lead to massive replenishing of the most aggressive cancer cell population. Therefore,
the key to successful strategy would be to prevent cancer cells to switch. To this end, a possible
future scenario might be to understand by microarray analysis the complex network of miRNAs
produced by each tumor and study ith the aid of computational analysis its possible impact on the
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plasticity of the cells. This could lead to identify possible critical pathways and genes to expoint
for therapeutic interventions, such as the development of a correct passive or active vaccination
strategies. The results reported in [11] provide a methodological guide to achieve these targets,
highlighting the importance of an interdisciplinary approach.
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Figure captions
Figure 1: Identification of CSCs. CSCs are identified by FACS sorting followed by transplantation in mice. The process
is then repeated.
Figure 2: Phenotypic switching and metastasis. In the CSC model, only the CSCs are able to initiate a tumor. Hence
metastasis can only occur if a CSC migrates to a distant site. If phenotypic switching is possible, however, normal cancer
cells (CC) can migrate and then switch into a CSC, initiating the metastatis.
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